Abstract
Angiosarcoma (AS) is an aggressive malignancy with poor prognosis, and a 5-year survival rate of approximately 10%.
However, the guideline for the optimal treatment has not yet been well established.
The group study for AS of the Japanese Association of Dermatologic Surgery suggested that the 1-to 2-cm surgical margin group receives a significant overall survival benefit.
Moreover, the pathological margin-free group also shows a significantly improved overall survival rate.
In this study, the chemotherapy group was also observed to have experienced a significantly improved overall survival rate.
Therefore the optimal treatment is the resection of the tumor, preferably with negative margin. In addition, the initial chemotherapy may inhibit metastases.
The realization of complete resection thus plays an important role in the improvement of the AS prognosis.
We hope to prepare promptly a TNM staging manual, and to establish the appropriate adjuvant therapy for AS patients.[Skin Cancer (Japan) 2010 ; 25 : 282-287]
